Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Ovarian Neoplasms 2Glioma 2Glioblastoma 2Brain Neoplasms 2Wilms Tumor 1Sarcoma 1Rhabdomyosarcoma 1Retroperitoneal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Peritoneal Cavity Cancer 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Mesothelioma, Malignant 1High Grade Serous Ovarian 1Gliosarcoma 1Gastrointestinal Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma 1Astrocytoma 1Appendiceal Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Cytoreduction Surgical Procedures × Clear all
NCT01257594 2023-05-25

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Columbia University

Phase 1 Completed
22 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02238496 2023-05-25

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Columbia University

Phase 1 Completed
10 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡